公开(公告)号：US20190256607A1

公开(公告)日：2019-08-22

申请号：US16287533

申请日：2019-02-27

Applicant: AMGEN INC.

Inventor： Hong Sun ,  Eduardo Dunayevich ,  Robert A. Lenz ,  Gabriel Vargas

IPC: C07K16/28

Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

公开(公告)号：US11466090B2

公开(公告)日：2022-10-11

申请号：US16287533

申请日：2019-02-27

Applicant: AMGEN INC.

Inventor： Hong Sun ,  Eduardo Dunayevich ,  Robert A. Lenz ,  Gabriel Vargas

IPC: C07K16/28 ,  A61K39/00

Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

公开(公告)号：US10259877B2

公开(公告)日：2019-04-16

申请号：US15136736

申请日：2016-04-22

Applicant: AMGEN INC.

Inventor： Hong Sun ,  Eduardo Dunayevich ,  Robert A. Lenz ,  Gabriel Vargas

IPC: A61K39/00 ,  C07K16/28

Abstract: The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.